Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery invests in high-throughput screening capability

At Sygnature Discovery we have now added in-house high-throughput screening (HTS) to our range of drug discovery services, backed up by our new Leadfinder compound library.

HTS allows many thousands of molecules to be tested for activity in a short period of time, providing a rapid way of identifying starting points for drug discovery programmes.

Sygnature’s new HTS system combines Titian Mosaic sample management technology with an automation platform from HighRes Biosolutions. Data analysis is facilitated using Genedata software. This is the first time these three leading vendors have worked together on the same system in order to create a high level of data fidelity during the screening operations.

The screening capability is underpinned by our Leadfinder library of 150,000 molecules. These were carefully selected by Sygnature’s team of experienced computational and medicinal chemists. A further 100,000 compounds will be designed and synthesised over the next five years.

‘The molecules were all selected to have lead-like molecular properties, and contain no undesirable functional groups,’ says John Unitt, Director of Bioscience at Sygnature Discovery. ‘Many commercial chemical libraries contain some molecules with features we would not want to incorporate into a drug lead. We have designed our Leadfinder library to avoid these problems.’

The library compounds are kept under dry, cool conditions and in an atmosphere of nitrogen to reduce the likelihood that they will oxidise or decompose on storage.

‘We decided to build our own HTS capability after feedback from our clients, especially around compound quality in many historical screening libraries’ says Colin Sambrook Smith, Sygnature’s Director of Computational Sciences & Informatics. ‘Having the capability housed within our Nottingham labs, where it can be integrated with our other hit-finding functions, will bring an enormous amount of additional value to our clients and their drug discovery projects.’

If you have any questions, would like to discuss HTS, Hit Identification, our capabilities or drug discovery in general then we’d love to hear from you. You can get in touch by using any of the contact forms or by emailing us at info@sygnaturediscovery.com

Latest News

View All

Sygnature Discovery invests in high-throughput screening capability

Sygnature Discovery moves US base to Kendall…

Sygnature Discovery raises over £2,776 for Cancer…

Sygnature Discovery named as Finalist in 2019…

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.

Opt In *